<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683421</url>
  </required_header>
  <id_info>
    <org_study_id>NAV3-23</org_study_id>
    <nct_id>NCT02683421</nct_id>
  </id_info>
  <brief_title>Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging</brief_title>
  <official_title>Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Navidea Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Navidea Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects
      with active RA and concordance with clinical symptomology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While many types of cells, including T-cells, B-cells, dendritic cells and activated synovial
      fibroblasts contribute significantly to the establishment and maintenance of the pathology of
      rheumatoid arthritis (RA), (Ma et al., Noack et al., Bugatti et al., Boissier et al., Tran et
      al.) macrophages play a critical role in RA (Kinne et al.). They produce most of the tumor
      necrosis factor alpha (TNFα) that drives and perpetuates the inflammatory cycle in RA (Leizer
      et al., Westra et al., Hamilton et al., Keffer et al., Noack et al., Bugatti et al., Boissier
      et al., Tran et al., Kinne et al., Zwerina et al., Feldman et al., Schett et al.). In the
      synovial sublining of a joint affected by RA, macrophages are the dominant cell type (Kraan
      et al., Cutolo et al.). In the inflamed joint as a whole, macrophages in RA patients make up
      at least 30%-40% of all cells (Kennedy et al.). Furthermore, macrophages participate directly
      in the destruction of bone and cartilage (Ma et al.). Activated macrophage populations and
      synoviocytes are the predominant cell types at the interface between pannus and cartilage and
      secrete destructive proteases in abundance (Bresnihan et al.). As a result, it may not be
      surprising that synovial macrophage numbers—but not the numbers of other immune cell
      types—correlate with radiographically determined joint destruction in RA (Mulherin et al.,
      Yanni et al.). While macrophages may play a role in other pathologies that cause joint pain
      and inflammation, the degree to which macrophages are involved in the pathological process of
      RA and the sheer mass or volume of macrophages that infiltrate the joints inflamed due to RA
      differentiates RA from other rheumatic diseases. Therefore, detection of the density or
      numbers of macrophages in inflamed joints may permit differentiation of patients with RA from
      those with other causes of arthritis. In addition, it is known that the RA pathology begins
      significantly before, perhaps years before, the onset of symptoms (i.e., joint pain and
      inflammation) and well before the beginning of bone destruction (Deane et al., El-Gabalawy et
      al.). Macrophage infiltration of synovial tissues precedes development of clinical signs of
      RA in animal studies (Kraan et al.). In humans, macrophage infiltrations of synovial tissues
      are present when RA patients first develop clinical symptoms (Demoruelle et al., van de Sande
      et al.). Therefore, detection of the density or numbers of macrophages in inflamed joints may
      facilitate more sensitive and specific identification of RA patients as soon as they present
      with symptoms and early in the course of their illnesses when DMARDs are likely to be most
      effective.

      An interesting and important observation that has been made in many studies is that the
      number of macrophages in synovial tissue, and particularly in the synovial sublining,
      declines in RA patients when they are given DMARD therapy (Hamilton et al.). Furthermore, the
      degree to which synovial macrophage numbers decline is correlated with the magnitude of the
      DMARD (DAS28) with changes in sublining macrophage numbers as determined by biopsies and
      found a significant correlation between the change in the number of macrophages and the
      change in DAS28 (Pearson correlation 0.874, p &lt; 0.01) ( Haringman et al.). The authors of
      this study have confirmed these findings in two additional studies, which used slightly
      different methodologies (Bresnihan et al., Bresnihan et al.). This correlation between
      declining macrophage numbers and the efficacy of DMARD therapy appears to be largely
      independent of the kind of DMARD therapy being investigated (Hamilton et al., Kinne et al.,
      Franz et al., Kraan et al., Catrina et al., Cunnane et al., Vieira-Sousa et al.). These
      findings indicate that assaying the number of macrophages in inflamed joints of patients with
      RA could be used as an objective measure of the efficacy of DMARD therapy. These findings
      further suggest that assaying the number of macrophages in inflamed joints of patients with
      RA could be used in clinical studies as a biomarker of clinical response for potential new RA
      therapeutics. The problem with current methodologies is that macrophage numbers and densities
      need to be determined with synovial biopsies. This is obviously an invasive procedure that
      samples only a small portion of the inflamed synovial tissue and is painful and unpleasant
      for the patient. What would be preferable and likely more accurate is an imaging protocol,
      such as the one proposed in this application, that can assay synovial macrophages more
      completely and less invasively.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Localization of Tc 99m Tilmanocept by Planar and SPECT/CT Imaging in Subjects With Active RA and Concordance With Swollen/Tender Joints</measure>
    <time_frame>Swollen/tender joints assessment at baseline and Tc 99m tilmanocept localization at 2-3 hours and 4-6 hours after administration on Day 1</time_frame>
    <description>The primary endpoint was to compare the cumulative total of anatomical zones of active RA (which were clinically defined by a swollen/tender classification during the DAS28 joint count assessment performed at baseline) with Tc 99m tilmanocept localization observed at 2-3 hours and at 4-6 hours after administration on Day 1. Tc 99m tilmanocept localization is defined by accumulation of radioactivity at an intensity greater than background, which was qualitatively determined by the central reader's visual assessment of the acquired images .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-dependent Tc 99m Tilmanocept Localization Intensity by Planar and SPECT/CT Imaging</measure>
    <time_frame>2-4 hours and 4-6 hours</time_frame>
    <description>Tc 99m tilmanocept localization intensity on planar imaging was compared among dose/disease groups. Localization intensity was quantitatively analyzed by observing average voxel intensity in regions of interest, which were drawn over areas of increased uptake in the RA-affected joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Localization Intensity of Tc 99m Tilmanocept by Planar Imaging in Regions of Interest Relative to Background in All Dose Groups</measure>
    <time_frame>2-4 hours and 4-6 hours</time_frame>
    <description>Tc 99m tilmanocept localization intensity on planar imaging relative to localization intensity in corresponding background regions was calculated (percent of background) for each region of interest and averaged for each dose/disease group.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RA group:200 mcg tilmanocept with 2 mCi Tc 99m</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tilmanocept</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>Lymphoseek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has provided written informed consent with HIPPA authorization before the
             initiation of any study-related procedures.

        CONTROLS:

          -  The subject is between 21-45 years of age at the time of consent.

          -  The subject has not experienced joint pain for at least 4 weeks prior to the consent
             date and is deemed to be clinically free of any inflammatory disease(s).

        ACTIVE RHEUMATOID ARTHRITIS

          -  The subject is at least 21 years of age at the time of consent.

          -  The subject has moderate to severe RA, based on either the 1987American College of
             Rheumatology (ACR) score of ≥ 4/7 or the 2010 ACR/EULAR score of ≥ 6/10.

          -  The subject has a DAS28 of &gt;4.4 (using the ESR).

          -  If the subject is on methotrexate, they have been at a stable dose for &gt; 4 weeks prior
             to the screening visit.

          -  If the subject is on biologic therapy, they have been at a stable dose &gt; 8 weeks prior
             to the screening visit.

          -  If the subject is on non-steroidal anti-inflammatories (NASIDS) or oral
             corticosteroids, it is ≤ 10mgmg/day or equivalent, and has been at a stable dose for &gt;
             4 weeks prior to the screening visit.

        Exclusion Criteria:

          -  The subject is pregnant or lactating.

          -  BMI &gt;32.0.

          -  The subject has had or is currently receiving chemotherapy for a non-inflammatory
             related condition or radiation therapy.

        Chronic or persistent infection or has any condition that would, in the opinion of the
        examining physician, preclude their participation.

          -  The subject has a known allergy to or has had a reaction to dextran exposure.

          -  The subject has received an investigational product within 30 days prior to he Tc99m
             tilmanocept administration.

          -  The subject has received any radiopharmaceutical within 7 radioactive half-lives of
             that radiopharmaceutical prior to the administration of Tc 99m tilmanocept.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Blue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Navidea Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <results_first_submitted>September 17, 2019</results_first_submitted>
  <results_first_submitted_qc>October 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2019</results_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Tilmanocept</keyword>
  <keyword>Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control Subjects: 50 mcg/2 mCi Dose</title>
          <description>Healthy Volunteers: 50 mcg tilmanocept with 2 millicuries (mCi) Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="P2">
          <title>Controls Subjects: 200 mcg/2mCi Dose</title>
          <description>Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="P3">
          <title>RA Subjects: 50 mcg/2 mCi Dose</title>
          <description>Rheumatoid arthritis (RA) Group: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="P4">
          <title>RA Subjects: 200 mcg/2 mCi Dose</title>
          <description>RA group:200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control Subjects: 50 mcg/20 mCi Dose</title>
          <description>Healthy Volunteers: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="B2">
          <title>Control Subjects: 200 mcg/2 mCi Dose</title>
          <description>Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="B3">
          <title>RA Subjects: 50 mcg/2 mCi Dose</title>
          <description>RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="B4">
          <title>RA Subjects: 200 mcg/2 mCi Dose</title>
          <description>RA group:200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="7.86"/>
                    <measurement group_id="B2" value="32.3" spread="5.74"/>
                    <measurement group_id="B3" value="47" spread="16.33"/>
                    <measurement group_id="B4" value="56.8" spread="18.54"/>
                    <measurement group_id="B5" value="43.2" spread="15.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Localization of Tc 99m Tilmanocept by Planar and SPECT/CT Imaging in Subjects With Active RA and Concordance With Swollen/Tender Joints</title>
        <description>The primary endpoint was to compare the cumulative total of anatomical zones of active RA (which were clinically defined by a swollen/tender classification during the DAS28 joint count assessment performed at baseline) with Tc 99m tilmanocept localization observed at 2-3 hours and at 4-6 hours after administration on Day 1. Tc 99m tilmanocept localization is defined by accumulation of radioactivity at an intensity greater than background, which was qualitatively determined by the central reader's visual assessment of the acquired images .</description>
        <time_frame>Swollen/tender joints assessment at baseline and Tc 99m tilmanocept localization at 2-3 hours and 4-6 hours after administration on Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Subjects: 50 mcg/2 mCi Dose</title>
            <description>Healthy Volunteers: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects: 200 mcg/2 mCi Dose</title>
            <description>Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O3">
            <title>RA Subjects: 50 mcg/2 mCi Dose</title>
            <description>RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O4">
            <title>RA Subjects: 200 mcg/2 mCi Dose</title>
            <description>RA group:200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
        </group_list>
        <measure>
          <title>Localization of Tc 99m Tilmanocept by Planar and SPECT/CT Imaging in Subjects With Active RA and Concordance With Swollen/Tender Joints</title>
          <description>The primary endpoint was to compare the cumulative total of anatomical zones of active RA (which were clinically defined by a swollen/tender classification during the DAS28 joint count assessment performed at baseline) with Tc 99m tilmanocept localization observed at 2-3 hours and at 4-6 hours after administration on Day 1. Tc 99m tilmanocept localization is defined by accumulation of radioactivity at an intensity greater than background, which was qualitatively determined by the central reader's visual assessment of the acquired images .</description>
          <units>Joints</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total swollen/tender regions at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Tc localized regions at 2-3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Tc localized regions at 4-6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose-dependent Tc 99m Tilmanocept Localization Intensity by Planar and SPECT/CT Imaging</title>
        <description>Tc 99m tilmanocept localization intensity on planar imaging was compared among dose/disease groups. Localization intensity was quantitatively analyzed by observing average voxel intensity in regions of interest, which were drawn over areas of increased uptake in the RA-affected joints.</description>
        <time_frame>2-4 hours and 4-6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Subjects: 50 mcg/2 mCi Dose</title>
            <description>Healthy Volunteers: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects: 200 mcg/2 mCi Dose</title>
            <description>Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O3">
            <title>RA Subjects: 50 mcg/2 mCi Dose</title>
            <description>RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O4">
            <title>RA Subjects: 200 mcg/2 mCi Dose</title>
            <description>RA group:200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
        </group_list>
        <measure>
          <title>Dose-dependent Tc 99m Tilmanocept Localization Intensity by Planar and SPECT/CT Imaging</title>
          <description>Tc 99m tilmanocept localization intensity on planar imaging was compared among dose/disease groups. Localization intensity was quantitatively analyzed by observing average voxel intensity in regions of interest, which were drawn over areas of increased uptake in the RA-affected joints.</description>
          <units>Voxel Intensity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.483"/>
                    <measurement group_id="O2" value="0.97" spread="0.685"/>
                    <measurement group_id="O3" value="1.17" spread="0.520"/>
                    <measurement group_id="O4" value="1.16" spread="0.694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-6 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.442"/>
                    <measurement group_id="O2" value="1.00" spread="0.742"/>
                    <measurement group_id="O3" value="1.21" spread="0.422"/>
                    <measurement group_id="O4" value="1.13" spread="0.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Localization Intensity of Tc 99m Tilmanocept by Planar Imaging in Regions of Interest Relative to Background in All Dose Groups</title>
        <description>Tc 99m tilmanocept localization intensity on planar imaging relative to localization intensity in corresponding background regions was calculated (percent of background) for each region of interest and averaged for each dose/disease group.</description>
        <time_frame>2-4 hours and 4-6 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Subjects: 50 mcg/2 mCi Dose</title>
            <description>Healthy Volunteers: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O2">
            <title>Control Subjects: 200 mcg/2 mCi Dose</title>
            <description>Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O3">
            <title>RA Subjects: 50 mcg/2 mCi Dose</title>
            <description>RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
          <group group_id="O4">
            <title>RA Subjects: 200 mcg/2 mCi Dose</title>
            <description>RA group:200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
          </group>
        </group_list>
        <measure>
          <title>Localization Intensity of Tc 99m Tilmanocept by Planar Imaging in Regions of Interest Relative to Background in All Dose Groups</title>
          <description>Tc 99m tilmanocept localization intensity on planar imaging relative to localization intensity in corresponding background regions was calculated (percent of background) for each region of interest and averaged for each dose/disease group.</description>
          <units>Percent difference from background</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="4.471"/>
                    <measurement group_id="O2" value="-9.21" spread="5.178"/>
                    <measurement group_id="O3" value="1.59" spread="6.309"/>
                    <measurement group_id="O4" value="9.11" spread="25.939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.32" spread="4.692"/>
                    <measurement group_id="O2" value="-6.74" spread="5.326"/>
                    <measurement group_id="O3" value="3.31" spread="14.544"/>
                    <measurement group_id="O4" value="16.34" spread="25.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Healthy Volunteers: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Healthy Volunteers: 200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>RA Group: 50 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4</title>
          <description>RA group:200 mcg tilmanocept with 2 mCi Tc 99m
Tilmanocept</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>probably related to tilmanocept injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>Pain at injection site for 5 days following injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <description>probably related to tilmanocept injection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and make modifications to the publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bonnie C. Abbruzzese, MS, RD</name_or_title>
      <organization>Navidea Biopharmaceuticals</organization>
      <phone>614-822-2327</phone>
      <email>babbruzzese@navidea.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

